Key
Management

We are a pharmaceutical development
company with experienced executives
and a shared vision to improve the
standard of cancer care.

NEW fiona

Ningfeng Fiona Li, MD, PhD, MSc
Co-founder, CEO & Executive Director

Specialist in Clinical Oncology, with extensive research experience in tumour biology and carcinogenesis with publications in high impact journals.

Founder of London Nanjing Life Science (China) Ltd and Suzhou NG Biomedicine Ltd and developed several biotech reagent products, disinfectant products and small molecule pharmaceutical products through prototyping, clinical trials and recently marketing.

ImageCrop 4

Dr Laurence Reilly, MD ML
Non-Executive Director & Chairman

Dr Laurence Reilly is a medical doctor by training and serves as Senior independent Non-Executive Director for Immupharma, an AIM-listed specialty biopharma company based in London. Dr Reilly also serves as Vice President, Head of Clinical, Research & Investments working with Royalty Pharma, a New York based life science investment company focussing on the acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Dr Reilly previously served as Chief Medical Officer at Cellectar Biosciences, New Jersey, a late-stage oncology biotech company, and as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor. Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

ImageCrop 1

Darren Fergus,
Non-Executive Director

With three decades of experience across big Pharma, biotech, and medtech, Darren Fergus has a deep understanding of healthcare.
For more than a decade he has led organisations in Europe, the UK, and Ireland.  Darren is CEO and co-founder of Profionics, President of Tweidpharma, Non-Executive Director of VasoDynamics, and Lay Trustee of the Intensive Care Society.

ImageCrop 2

Alexandra (Wills) Hughes-Wilson
Non-Executive Director

Ms Wills Hughes-Wilson, executive at Mereo BioPharma, has a background in law, with over 20 years’ experience in the biopharma industry with increasing responsibility and leadership roles in US and European-based publicly traded biotechnology companies across a broad range of therapeutic areas, including rare diseases, oncology and other speciality pharma. The main focus of her recent operational roles includes defining pathways to market and providing strategic input into development programmes as well as product launch preparation and commercial delivery.

ImageCrop 3

Hilary Birrell
 Executive Director

Mrs Birrell is a biochemist and clinical trial specialist with over 30 years’ experience in multiple indications across Phases I-IV of drug development. Her early career in AstraZeneca was followed by 20 years of consultancy experience as the owner/Director of Carnegie Clinical Research Ltd, a Clinical Trial Management CRO, since 2010. She has been an executive team member of VasoDynamics since 2021 and has deep understanding of the company’s development scope and operational hurdles